Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties

Citations Over TimeTop 23% of 2013 papers

Abstract

Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone 3, to differentiate the pharmacokinetic profile versus the lead clinical compounds. An in vitro and in vivo clearance data set revealed a lack of correlation; however, when compounds with <5% free fraction were excluded, a more predictable correlation was observed. Compounds with log P between 3 and 4 were likely to have significant free fraction, so we designed compounds in this range to give more predictable clearance values. This strategy produced compounds with desirable in vivo half-lives, ultimately leading to the discovery of compound 46. The progression of compound 46 was halted due to the contemporaneous marketing and clinical withdrawal of other centrally acting CB1 antagonists; however, the design strategy successfully delivered a potent CB1 antagonist with the desired pharmacokinetic properties and a clean off-target profile.

Related Papers

• → Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes(2002)101 cited
• → Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles(1992)141 cited
• → Cannabinoid–improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor(2006)9 cited
• → Pharmacological characterization of the cannabinoid CB1 receptor PET ligand ortholog, [3H]MePPEP(2010)6 cited
• → Cannabinoid Ligand-Receptor Signaling During Early Pregnancy in the Mouse(1999)3 cited